Treatment of malignant pleural mesothelioma: current status and future directions.
Previously considered to be rare, malignant pleural mesothelioma (MPM) is a highly aggressive tumour that has become a very important issue over recent years due to its poor prognosis and its increasing incidence mostly linked to previous asbestos exposure. An optimal treatment for MPM is not established yet; new therapies and predictive tools are still needed in the management of this cancer. Thus the aim of this review is to provide clinicians clear and up-to-dated data on the latest therapeutic strategies for MPM patients in 2010. The guidelines recently proposed by the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) taskforce are summarized here. The authors also briefly reviewed the future directions in MPM treatment including targeted therapies, gene or cell therapies.
Dhalluin
X
X
Pneumologie et Oncologie Thoracique, Hôpital Calmette - CHRU de Lille, Lille Cedex, France.
Scherpereel
A
A
D003131:Combined Modality Therapy; D006801:Humans; D008654:Mesothelioma / Q000473:pathology / Q000628:therapy*; D010997:Pleural Neoplasms / Q000473:pathology / Q000628:therapy*